David Groheux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6961026/publications.pdf

Version: 2024-02-01

63	3,119	186265	155660
papers	citations	28 h-index	55 g-index

71	71	71	3030
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy. Cancers, 2022, 14, 1331.	3.7	2
2	FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer. Seminars in Nuclear Medicine, 2022, 52, 508-519.	4.6	22
3	Breast cancer: initial workup and staging with FDG PET/CT. Clinical and Translational Imaging, 2021, 9, 221-231.	2.1	34
4	Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, xxx.	4.9	2
5	Good clinical practice recommendations for the use of PET/CT in oncology. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 28-50.	6.4	85
6	18FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher. Annals of Surgical Oncology, 2020, 27, 1708-1709.	1.5	1
7	Interim [18F]Fluorodeoxyglucoseâ€“Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2019, 37, 2091-2092.	1.6	1
8	Recommandations et rÃ©fÃ©rentiels. Medecine Nucleaire, 2019, 43, 1-4.	0.2	0
9	Now Is the Time to Use ¹⁸F-FDG PET/CT to Optimize Neoadjuvant Treatment in Triple-Negative Breast Cancer!. Journal of Nuclear Medicine, 2018, 59, 863-864.	5.0	3
10	Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1279-1288.	6.4	21
11	Role of Fludeoxyglucose in Breast Cancer. PET Clinics, 2018, 13, 395-414.	3.0	21
12	18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. Oncotarget, 2018, 9, 16343-16353.	1.8	15
13	18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. Breast Cancer Research, 2017, 19, 3.	5.0	67
14	Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1145-1154.	6.4	65
15	FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1417-1419.	6.4	14
16	¹⁸F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer. Journal of Nuclear Medicine, 2017, 58, 683.1-683.	5.0	5
17	FDG PET and FES PET Predict PFS on Endocrine Therapyâ€”Letter. Clinical Cancer Research, 2017, 23, 3474-3474.	7.0	0
18	Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection. Journal of Clinical Oncology, 2016, 34, 2673-2674.	1.6	3

#	Article	IF	Citations
19	FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review. Diagnostic and Interventional Imaging, 2016, 97, 1003-1017.	3.2	103
20	Is 18FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1571-1573.	6.4	2
21	Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies. Medecine Nucleaire, 2016, 40, 65-71.	0.2	0
22	18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 983-993.	6.4	58
23	¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 17S-26S.	5.0	135
24	¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen. Journal of Nuclear Medicine, 2016, 57, 536-543.	5.0	40
25	TEP/TDM au 18FDG dans le bilan initial et lâ€™Ã©valuation prÃ©coce de la chimiothÃ©rapie nÃ©oadjuvante du cancer du sein. Medecine Nucleaire, 2015, 39, 315-326.	0.2	0
26	Pathological complete response in breast cancer. Lancet, The, 2015, 385, 114.	13.7	8
27	Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 377-385.	6.4	46
28	Breast infiltration by relapsed acute lymphoblastic leukaemia on FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 811-812.	6.4	3
29	Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. Radiology, 2015, 277, 358-371.	7.3	72
30	Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1682-1691.	6.4	63
31	Concerning pretreatment 18F-FDG PET/CT imaging in patients with large or locally advanced breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1801-1803.	6.4	1
32	Baseline Tumor ¹⁸F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2â˜ Breast Cancer. Journal of Nuclear Medicine, 2015, 56, 824-831.	5.0	48
33	Breast Cancer Staging: To Which Women Should ¹⁸F-FDG PET/CT Be Offered?. Journal of Nuclear Medicine, 2015, 56, 1293.1-1293.	5.0	6
34	¹⁸F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multiâ€“Cancer Site Patient Cohort. Journal of Nuclear Medicine, 2015, 56, 38-44.	5.0	374
35	Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis. Anticancer Research, 2015, 35, 1729-34.	1.1	6
36	Breast Cancer Patient With an Uncommon Lymphatic Drainage Evidenced by SPECT/CT. Clinical Nuclear Medicine, 2014, 39, e176-e179.	1.3	6

#	Article	IF	Citations
37	Predicting pathological complete response in breast cancer early. Lancet Oncology, The, 2014, 15, 1415-1416.	10.7	14
38	Role of SPECT/CT in Sentinel Lymph Node Detection in Patients With Breast Cancer. Clinical Nuclear Medicine, 2014, 39, 431-436.	1.3	30
39	18F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. European Journal of Radiology, 2014, 83, 1925-1933.	2.6	22
40	Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. European Journal of Cancer, 2014, 50, 1864-1871.	2.8	53
41	Estrogen receptorâ€positive/human epidermal growth factor receptor 2â€negative breast tumors. Cancer, 2013, 119, 1960-1968.	4.1	47
42	Performance of FDG PET/CT in the Clinical Management of Breast Cancer. Radiology, 2013, 266, 388-405.	7.3	224
43	Comparison Between 18F-FDG PET Imageâ€“Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Nuclear Medicine, 2013, 54, 341-349.	5.0	74
44	¹⁸F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging. Journal of Nuclear Medicine, 2013, 54, 5-11.	5.0	114
45	Cryptorchidism as a potential source of misinterpretation in 18FDG-PET imaging in restaging lymphoma patients. Biomedicine and Pharmacotherapy, 2013, 67, 533-538.	5.6	5
46	Whole-body 18FDGâ€“PET/CT or whole-body gadolinium-enhanced MRI for distant staging?. Annals of Oncology, 2013, 24, 9-13.	1.2	4
47	HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. British Journal of Cancer, 2013, 109, 1157-1164.	6.4	59
48	Variation of Liver SUV on 18FDG-PET/CT Studies in Women With Breast Cancer. Clinical Nuclear Medicine, 2013, 38, 422-425.	1.3	30
49	Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 1879-1887.	6.3	133
50	Triple-Negative Breast Cancer: Early Assessment with ¹⁸F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse. Journal of Nuclear Medicine, 2012, 53, 249-254.	5.0	91
51	Hypoxia Imaging of Uterine Cervix Carcinoma With 18F-FETNIM PET/CT. Clinical Nuclear Medicine, 2012, 37, 1065-1068.	1.3	27
52	FDG PET/CT in Ovarian Cancer. Clinical Nuclear Medicine, 2012, 37, 54-56.	1.3	3
53	Lymphoscintigraphy Can Select Breast Cancer Patients for Internal Mammary Chain Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1081-1088.	0.8	37
54	Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsyâ€”FDG-PET/CT. PET Clinics, 2011, 6, 9-25.	3.0	6

#	Article	IF	Citations
55	Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 426-435.	6.4	337
56	Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 419-425.	6.4	64
57	The Yield of ¹⁸F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study. Journal of Nuclear Medicine, 2011, 52, 1526-1534.	5.0	99
58	The Sentinel Node Procedure in Breast Cancer: Nuclear Medicine as the Starting Point. Journal of Nuclear Medicine, 2011, 52, 405-414.	5.0	82
59	The evolving role of PET/CT in breast cancer. Nuclear Medicine Communications, 2010, 31, 271-273.	1.1	19
60	Should FDG PET/CT be used for the initial staging of breast cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1539-1542.	6.4	22
61	Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies. Nuclear Medicine Communications, 2009, 30, 926-933.	1.1	4
62	Effect of 18F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 695-704.	0.8	114
63	Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help. Journal of Clinical Oncology, 0, , .	1.6	2